OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial
Annemarie B. van der Aart‐van der Beek, Lindsay E. Clegg, Robert C. Penland, et al.
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 12, pp. 2493-2498
Open Access | Times Cited: 31
Annemarie B. van der Aart‐van der Beek, Lindsay E. Clegg, Robert C. Penland, et al.
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 12, pp. 2493-2498
Open Access | Times Cited: 31
Showing 1-25 of 31 citing articles:
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
Ahmed M. Shaman, Stephen C. Bain, George L. Bakris, et al.
Circulation (2021) Vol. 145, Iss. 8, pp. 575-585
Open Access | Times Cited: 171
Ahmed M. Shaman, Stephen C. Bain, George L. Bakris, et al.
Circulation (2021) Vol. 145, Iss. 8, pp. 575-585
Open Access | Times Cited: 171
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
Hiddo J.L. Heerspink, Naveed Sattar, Imre Pávó, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 11, pp. 774-785
Open Access | Times Cited: 164
Hiddo J.L. Heerspink, Naveed Sattar, Imre Pávó, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 11, pp. 774-785
Open Access | Times Cited: 164
Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials
Hiddo J.L. Heerspink, Ellen M. Apperloo, Melanie J. Davies, et al.
Diabetes Care (2023) Vol. 46, Iss. 4, pp. 801-810
Open Access | Times Cited: 53
Hiddo J.L. Heerspink, Ellen M. Apperloo, Melanie J. Davies, et al.
Diabetes Care (2023) Vol. 46, Iss. 4, pp. 801-810
Open Access | Times Cited: 53
Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future
Irene Caruso, Francesco Giorgino
Endocrine (2024) Vol. 84, Iss. 3, pp. 822-835
Open Access | Times Cited: 17
Irene Caruso, Francesco Giorgino
Endocrine (2024) Vol. 84, Iss. 3, pp. 822-835
Open Access | Times Cited: 17
Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes
Patrizia Natale, Suetonia C. Green, David J. Tunnicliffe, et al.
Cochrane library (2025) Vol. 2025, Iss. 2
Closed Access | Times Cited: 1
Patrizia Natale, Suetonia C. Green, David J. Tunnicliffe, et al.
Cochrane library (2025) Vol. 2025, Iss. 2
Closed Access | Times Cited: 1
Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical study
Annemarie B. van der Aart‐van der Beek, Ellen M. Apperloo, Niels Jongs, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 6, pp. 1758-1768
Open Access | Times Cited: 16
Annemarie B. van der Aart‐van der Beek, Ellen M. Apperloo, Niels Jongs, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 6, pp. 1758-1768
Open Access | Times Cited: 16
Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review
Katherine Young, Eram Haider McInnes, Robert Massey, et al.
Communications Medicine (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 15
Katherine Young, Eram Haider McInnes, Robert Massey, et al.
Communications Medicine (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 15
Potential Mediators for Treatment Effects of Novel Diabetes Medications on Cardiovascular and Renal Outcomes: A Meta‐Regression Analysis
José M. Rodriguez‐Valadez, Malak Tahsin, Umesh Masharani, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 4
Open Access | Times Cited: 6
José M. Rodriguez‐Valadez, Malak Tahsin, Umesh Masharani, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 4
Open Access | Times Cited: 6
Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms
Gianluigi Savarese, Javed Butler, Lars H. Lund, et al.
Cardiovascular Research (2021) Vol. 118, Iss. 10, pp. 2231-2252
Open Access | Times Cited: 32
Gianluigi Savarese, Javed Butler, Lars H. Lund, et al.
Cardiovascular Research (2021) Vol. 118, Iss. 10, pp. 2231-2252
Open Access | Times Cited: 32
Potential kidney protective effects of glucagon‐like peptide‐1 receptor agonists
Philippa Trevella, Elif I. Ekinci, Richard J. MacIsaac
Nephrology (2024) Vol. 29, Iss. 8, pp. 457-469
Open Access | Times Cited: 4
Philippa Trevella, Elif I. Ekinci, Richard J. MacIsaac
Nephrology (2024) Vol. 29, Iss. 8, pp. 457-469
Open Access | Times Cited: 4
Recent advances in the treatment of patients with obesity and chronic kidney disease
Roshaida Abdul Wahab, Ricardo V. Cohen, Carel W. le Roux
Annals of Medicine (2023) Vol. 55, Iss. 1
Open Access | Times Cited: 10
Roshaida Abdul Wahab, Ricardo V. Cohen, Carel W. le Roux
Annals of Medicine (2023) Vol. 55, Iss. 1
Open Access | Times Cited: 10
Treatment and practical considerations of diabetic kidney disease
Yara Bilen, Allaa Almoushref, Kenda Alkwatli, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 10
Yara Bilen, Allaa Almoushref, Kenda Alkwatli, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 10
SIRT1-dependent deacetylation of Txnip H3K9ac is critical for exenatide-improved diabetic kidney disease
Meijun Wang, Xiang Cai, Riying Liang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115515-115515
Open Access | Times Cited: 8
Meijun Wang, Xiang Cai, Riying Liang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115515-115515
Open Access | Times Cited: 8
Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation
Lale A. Ertuğlu, Esteban Porrini, Mads Hornum, et al.
Transplant International (2021) Vol. 34, Iss. 8, pp. 1341-1359
Closed Access | Times Cited: 15
Lale A. Ertuğlu, Esteban Porrini, Mads Hornum, et al.
Transplant International (2021) Vol. 34, Iss. 8, pp. 1341-1359
Closed Access | Times Cited: 15
Glucagon-like peptide 1(GLP-1) receptor agonists in the management of the patient with type 2diabetes mellitus and chronic kidney disease: an approach for the nephrologist
Aleix Cases
Nefrología (English Edition) (2023) Vol. 43, Iss. 4, pp. 399-412
Open Access | Times Cited: 6
Aleix Cases
Nefrología (English Edition) (2023) Vol. 43, Iss. 4, pp. 399-412
Open Access | Times Cited: 6
Richard J. MacIsaac, Philippa Trevella, Elif I. Ekinci
Journal of Diabetes (2024) Vol. 16, Iss. 10
Open Access | Times Cited: 2
Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
Jun Inaishi, Yoshifumi Saisho
Clinical Pharmacology Advances and Applications (2022) Vol. Volume 14, pp. 19-26
Open Access | Times Cited: 8
Jun Inaishi, Yoshifumi Saisho
Clinical Pharmacology Advances and Applications (2022) Vol. Volume 14, pp. 19-26
Open Access | Times Cited: 8
Kidney transcriptomics signature of prospective rapid diabetic kidney disease progression
Dianne Acoba, Anna Levin, Anna Witasp, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Dianne Acoba, Anna Levin, Anna Witasp, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Utilization of glucagon‐like peptide‐1 receptor agonists and changes in clinical characteristics in patients with type 2 diabetes by chronic kidney disease stage in Japan: A descriptive observational study using a nationwide electronic medical records database
Naoki Hirose, Naoto Tsujimoto, Taeko Katayose, et al.
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 3, pp. 486-498
Open Access | Times Cited: 8
Naoki Hirose, Naoto Tsujimoto, Taeko Katayose, et al.
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 3, pp. 486-498
Open Access | Times Cited: 8
Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs
Hyo Jin Kim, Sang Soo Kim, Sang Heon Song
The Korean Journal of Internal Medicine (2022) Vol. 37, Iss. 3, pp. 502-519
Open Access | Times Cited: 6
Hyo Jin Kim, Sang Soo Kim, Sang Heon Song
The Korean Journal of Internal Medicine (2022) Vol. 37, Iss. 3, pp. 502-519
Open Access | Times Cited: 6
Agonistas del receptor de péptido similar al glucagón tipo 1 (GLP-1) en el manejo del paciente con diabetes mellitus tipo 2. Una aproximación para el nefrólogo
Aleix Cases
Nefrología (2022) Vol. 43, Iss. 4, pp. 399-412
Open Access | Times Cited: 6
Aleix Cases
Nefrología (2022) Vol. 43, Iss. 4, pp. 399-412
Open Access | Times Cited: 6
Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors
Katherine Young, Eram Haider McInnes, Robert Massey, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Katherine Young, Eram Haider McInnes, Robert Massey, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers
Sok Cin Tye, Sieta T. de Vries, Johannes F.E. Mann, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 5
Sok Cin Tye, Sieta T. de Vries, Johannes F.E. Mann, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 5
Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors
Anthony T. P. Chan, Sydney C.W. Tang
Kidney Research and Clinical Practice (2022) Vol. 41, Iss. 6, pp. 682-698
Open Access | Times Cited: 5
Anthony T. P. Chan, Sydney C.W. Tang
Kidney Research and Clinical Practice (2022) Vol. 41, Iss. 6, pp. 682-698
Open Access | Times Cited: 5
Potential cardiorenal benefits of efpeglenatide in diabetes
Jacques Ma, Mark E. Cooper
Nature Reviews Nephrology (2021) Vol. 17, Iss. 11, pp. 708-709
Closed Access | Times Cited: 5
Jacques Ma, Mark E. Cooper
Nature Reviews Nephrology (2021) Vol. 17, Iss. 11, pp. 708-709
Closed Access | Times Cited: 5
